The last 5 years have witnessed a significant increase in the number of clinical studies based on human pluripotent stem cells (hPSCs). In parallel, concern is increasing about the proliferation of unregulated stem cell treatments worldwide. Regulated clinical testing is a de facto standard to establish the safety and efficacy of new cell therapies, yet reliable information on clinical studies involving hPSCs is scattered. Our analysis of a multitude of resources found 54 clinical studies involving several types of hPSCs, which are performed in ten countries. While the majority of those studies is based on human embryonic stem cells (hESCs), clinical studies involving human induced pluripotent stem cells increased more strongly in the past 2 years than the number of hESC-based studies. A publicly accessible database was created using the human pluripotent stem cell registry (https://hpscreg.eu) platform, providing a steadily updated comprehensive overview on hPSC-based clinical studies performed worldwide.

在过去的5年中，基于人类多能干细胞（hPSC）的临床研究数量显着增加。同时，世界范围内对不受监管的干细胞治疗方法的扩散的关注也在增加。规范的临床测试是确立新细胞疗法安全性和有效性的事实上的标准，但是涉及hPSC的临床研究的可靠信息却很少。我们对多种资源的分析发现，涉及10种国家的54种涉及几种hPSC类型的临床研究。尽管这些研究大多数是基于人类胚胎干细胞（hESCs），但与人类基于hESC的研究相比，涉及人类诱导的多能干细胞的临床研究在过去两年中的增长更为强劲。